Table 5.

Five-Year Survival Estimates in the Two Study Arms

Patient No. Ciprofloxacin + Metronidazole5-150Patient No. Ciprofloxacin5-150P Value5-151
All patients  68  49% ± 6%  66  42% ± 6% NS  
Donors  
 HLA-identical siblings  40 55% ± 8%  40  38% ± 8%  NS  
 Alternative donors  28  39% ± 9%  26  50% ± 10%  NS 
Disease stages  
 Early stages  35  60% ± 8%  41 51% ± 8%  NS  
 Advanced stages  33 36% ± 8%  25  28% ± 9%  NS  
Donors and disease stages  
 HLA-identical siblings  
  Early stages  20 60% ± 11%  28  46% ± 9%  NS  
  Advanced stages  20  50% ± 11%  12  17% ± 11%  NS 
 Alternative donors  
  Early stages  15 60% ± 13%  13  61% ± 13%  NS  
  Advanced stages  13  15% ± 10%  13  38% ± 13% NS 
Patient No. Ciprofloxacin + Metronidazole5-150Patient No. Ciprofloxacin5-150P Value5-151
All patients  68  49% ± 6%  66  42% ± 6% NS  
Donors  
 HLA-identical siblings  40 55% ± 8%  40  38% ± 8%  NS  
 Alternative donors  28  39% ± 9%  26  50% ± 10%  NS 
Disease stages  
 Early stages  35  60% ± 8%  41 51% ± 8%  NS  
 Advanced stages  33 36% ± 8%  25  28% ± 9%  NS  
Donors and disease stages  
 HLA-identical siblings  
  Early stages  20 60% ± 11%  28  46% ± 9%  NS  
  Advanced stages  20  50% ± 11%  12  17% ± 11%  NS 
 Alternative donors  
  Early stages  15 60% ± 13%  13  61% ± 13%  NS  
  Advanced stages  13  15% ± 10%  13  38% ± 13% NS 
F5-150

Product-limit estimates ± standard errors.

F5-151

Comparisons between product-limits estimates by log-rank test.

View Large